Market Cap: $3.22B
CI
Celcuity Inc.
CELC
NASDAQUSD
Market Cap: $3.22B
Celcuity Prepares for Future Growth Amid Recent Earnings Release Celcuity, a biotechnology firm focused on advancing cancer treatment through its innovative drug discovery platform, has recently repor…
Navigating the Landscape of Precision Medicine: Celcuity’s Strategic Focus on Cancer Therapeutics Celcuity, a clinical-stage biotechnology company, is making significant strides in the realm of precis…
Celcuity’s Strategic Positioning Amid Market Volatility Celcuity, a biotechnology company focused on developing innovative cancer therapies, navigates a challenging economic landscape marked by height…
Celcuity's Gedatolisib Advances Towards FDA Approval, Offering New Hope in Breast Cancer Treatment Celcuity Inc., a biopharmaceutical company focused on innovative cancer therapies, celebrates a pivot…
Celcuity’s Gedatolisib Gains FDA Acceptance, Paving the Way for Advanced Breast Cancer Treatment Celcuity Inc. achieves a significant milestone with the acceptance of its New Drug Application (NDA) fo…
Celcuity's Innovative Approach to Oncology: Transforming Cancer Treatment Celcuity, a clinical-stage biotechnology company, is at the forefront of revolutionizing cancer treatment through its propriet…
Celcuity's Innovative Approach to Cancer Treatment Gains Traction Celcuity, a biotechnology company focused on developing targeted treatments for cancer, is making significant strides in precision med…
Celcuity's Breakthrough in Breast Cancer Treatment: A Promising Future Ahead Celcuity Inc. has recently made significant strides in the realm of oncology with the announcement of positive topline resu…
Celcuity's Breakthrough in Breast Cancer Treatment: Implications of the VIKTORIA-1 Trial Results Celcuity Inc. has recently made headlines with the announcement of positive topline results from the PI…
Celcuity's VIKTORIA-1 Trial Results Propel Innovative Breast Cancer Treatment Forward Celcuity Inc. (CELC) announces significant progress in breast cancer treatment following positive topline results…